Systemic sclerosis: New insights in autoimmunity

Proceedings of the Society for Experimental Biology and Medicine

Volumn 222, Issue 1, 1999, Pages 1-8

  Kaal, Suzanne E J ^a   Van Den Hoogen, Frank H J ^a   De Jong, Elke M G J ^a   Viëtor, Henk E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNITY; DIFFERENTIAL DIAGNOSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOLOGY; MICROCHIMERISM; SEX DIFFERENCE; SHORT SURVEY; SYSTEMIC SCLEROSIS;

EID: 0032842920     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1373.1999.09991.x     Document Type: Short Survey

References (67)

1. Rubin E, Farber JL. Pathology, (2nd ed). Philadelphia: J.B. Lippincott Company, pp138-140, 1994.
2. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590, 1980.
3. Kumar P, Clark M. Clinical Medicine (3rd ed). London: Bailliere Tindall W.B. Saunders, pp1021-1022, 1994.
4. Nelson JL. Pregnancy, persistent microchimerism, and autoimmune disease. J Am Med Womens Assoc 53:31-2, 47, 1998.
5. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338:1186-1191, 1998.
6. Artlett CM, Welsh KI, Black CM, Jimenez SA. Fetal-maternal HLA compatibility confers susceptibility to systemic sclerosis. Immunogenetics 47:17-22, 1997.
7. Perez MI, Kohn SR. Systemic sclerosis. J Am Acad Dermatol 28:525-547, 1993.
8. Klippel JH, Dieppe PA. Rheumatology (2nd ed). London: Mosby International, 1998.
9. Reveille JD. Molecular genetics of systemic sclerosis. Curr Opin Rheumatol 7:522-528, 1995.
10. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 12:107-128, 1995.
11. De Jong EM, van den Hoogen FH. Gegeneraliseerde morphea. Nederlands Tijdschrift voor Dermatologie en Venereologie 7:273-275, 1997.
12. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Skouge JW, Webster SB, Whitaker DC, Butler B, Lowery BJ, Sontheimer RD, Callen JP, Camisa C, Provost TT, Tuffanelli DL. Guidelines of care for scleroderma and sclerodermoid disorders. American Academy of Dermatology. J Am Acad Dermatol 35:609-614, 1996.
13. Greenberg AS, Falanga V. Localized cutaneous manifestations. In: Sontheimer RD, Provost TT, Eds. Cutaneous Manifestations of Rheumatic Diseases. Baltimore: Williams and Wilkins, pp141-155, 1996.
14. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4, and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 287:193-197, 1995.
15. Postlethwaite AE. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 7:535-540, 1995.
16. Hynes RO. Integrins: A family of cell surface receptors. Cell 48:549-554, 1987.
17. Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of β-1 and β-2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 35:290-298, 1992.
18. Marrack P, Parker DC. T-cell selection: A little of what you fancy. Nature 368:397-398, 1994.
19. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular Biology of the Cell (3rd ed). New York: Garland Publishing Inc., pp1246-1248, 1994.
20. Nelson JL. Microchimerism and the causation of scleroderma. Scand J Rheumatol Suppl 107:10-13, 1998.
21. Farmer ER. Human cutaneous graft-versus-host disease. J Invest Dermatol 85:124s-128s, 1985.
22. Abbas AK, Lichtman AH, Pober JS. Cellular and Molecular Immunology (2nd ed). Philadelphia: W.B. Saunders Company, pp353-354, 1994.
23. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N, Kersey J, Filipovich A. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 51:1197-1203, 1991.
24. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: Microchimerism and allograft survival. Immunol Today 17:577-584, 1996.
25. van der Mast BJ, Hornstra N, Ruigrok MB, Claas FH, van Rood JJ, Lagaaij EL. Transfusion-associated graft-versus-host disease in immunocompetent patients: A self-protective mechanism. Lancet 343:753-757, 1994.
26. Shivdasani RA, Anderson KC. HLA homozygosity and shared HLA haplotypes in the development of transfusion-associated graft-versus-host disease. Leuk Lymphoma 15:227-234, 1994.
27. Prummer O, Bunjes D, Wiesneth M, Arnold R, Porzsolt F, Heimpel H. High-titre interferon-α antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 14:483-486, 1994.
28. Chosidow O, Bagot M, Vernant JP, Roujeau JC, Cordonnier C, Kuentz M, Wechsler J, Andre C, Touraine R, Revuz J. Sclerodermatous chronic graft-versus-host disease: Analysis of seven cases. J Am Acad Dermatol 26:49-55, 1992.
29. Parkman R. Chronic graft-versus-host disease. Curr Opin Hematol 5:22-25, 1998.
30. Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ. Cytokine expression in human cutaneous chronic graft-versus-host disease. Bone Marrow Transplant 17:1085-1092, 1996.
31. Kumpel GR, Annable CR, Cleveland MG, Jerrells TR, Patterson JC. Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J Immunol 144:84-93, 1990.
32. Barak V, Levi Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma 17:169-173, 1995.
33. Freemer CS, Farmer ER, Corio RL, Altomonte VL, Wagner JE, Vogelsang GB, Santos GW. Lichenoid chronic graft-versus-host disease occurring in a dermatomal distribution. Arch Dermatol 130:70-72, 1994.
34. Jacobsen N, Andersen HK, Skinhoj P, Ryder LP, Platz P, Jerne D, Faber V. Correlation between donor cytomegalovirus immunity and chronic graft-versus-host disease after allogeneic bone marrow transplantation. Scand J Haematol 36:499-506, 1986.
35. Burdick JF, Vogelsang GB, Smith WJ, Farmer ER, Bias WB, Kaufmann SH, Horn J, Colombani PM, Pitt HA, Perler BA, Merritt WT, Williams GM, Boitnott JK, Herlong HF. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med 318:689-691, 1988.
36. Nelson JL. Maternal-fetal immunology and autoimmune disease: Is some autoimmune disease auto-alloimmune or allo-autoimmune? Arthritis Rheum 39:191-194, 1996.
37. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci U S A 93:705-708, 1996.
38. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, Smith A, Bean MA, Ober C, Bianchi DW. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351:559-562, 1998.
39. Wagner FF, Flegel WA. Transfusion-associated graft-versus-host disease: Risk due to homozygous HLA haplotypes. Transfusion 35:284-291, 1995.
40. Thaler M, Shamiss A, Orgad S, Huszar M, Nussinovitch N, Meisel S, Gazit E, Lavee J, Smolinsky A. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med 321:25-28, 1989.
41. Otsuka S, Kunieda K, Kitamura F, Misawa K, Sasaoka I, Hirose M, Kasuya S, Saji S, Noma A. The critical role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease in immunocompetent patients. Transfusion 31:260-264, 1991.
42. Ober C. HLA and pregnancy: The paradox of the fetal allograft. Am J Hum Genet 62:1-5, 1998.
43. Bouma GJ, van Caubergh P, van Bree SP, Castelli Visser RM, Witvliet MD, van der Meer Prins EM, van Rood JJ, Claas FH. Pregnancy can induce priming of cytotoxic T lymphocytes specific for paternal HLA antigens that is associated with antibody formation. Transplantation 62:672-678, 1996.
44. Farrell A, Scerri L, Stevens A, Millard LG. Acute graft-versus-host disease with unusual cutaneous intracellular vacuolation in an infant with severe combined immunodeficiency. Pediatr Dermatol 12:311-313, 1995.
45. Antezak DF. Maternal antibody responses in pregnancy. Curr Opin Immunol 1:1135-1140, 1989.
46. Le Bouteiller P, Rodriguez AM, Mallet V, Girr M, Guillaudeux T, Lenfant F. Placental expression of HLA class I genes. Am J Reprod Immunol 35:216-225, 1996.
47. Claas FH, Gijbels Y, van der Velden-de Munck J, van Rood JJ. Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life. Science 241:1815-1817, 1988.
48. Zhang L, van Bree S, van Rood JJ, Claas FH. Influence of breast feeding on the cytotoxic T cell allorepertoire in man. Transplantation 52:914-916, 1991.
49. Keever CA, Abu-Hajir M, Graf W, McFadden P, Prichard P, O'Brien J, Flomenberg N. Characterization of the alloreactivity and antileukemia reactivity of cord blood mononuclear cells. Bone Marrow Transplant 15:407-419, 1995.
50. Bianchi DW. Current knowledge about fetal blood cells in the maternal circulation. J Perinat Med 26:175-178, 1998.
51. Lagaaij EL, Hennemann IP, Ruigrok M, de Haan MW, Persijn GG, Termijtelen A, Hendricks GF, Weimar W, Claas FH, van Rood JJ. Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 321:701-705, 1989.
52. Shivdasani RA, Haluska FG, Dock NL, Dover JS, Kineke EJ, Anderson KC. Brief report: Graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 328:766-770, 1993.
53. Wood KJ. New concepts in tolerance. Clin Transplant 10:93-99, 1996.
54. Elwood ET, Larsen CP, Maurer DH, Routenberg KL, Neylan JF, Whelchel JD, O'Brien DP, Pearson TC. Microchimerism and rejection in clinical transplantation. Lancet 349:1358-1360, 1997.
55. Adams DH, Hutchinson IV. Microchimerism and graft tolerance: Cause or effect? Lancet 349:1336-1337, 1997.
56. Kast WM, Van Twuyver E, Mooijaart RJ, Verveld M, Kamphuis AG, Melief CJ, De Waal LP. Mechanism of skin allograft enhancement across an H-2 class I mutant difference: Evidence for involvement of veto cells. Eur J Immunol 18:2105-2108, 1988.
57. Fink PJ, Shimonkevitz RP, Bevan MJ. Veto cells. Annu Rev Immunol 6:115-137, 1988.
58. Nelson JL. Microchimerism and autoimmune disease. N Engl J Med 338:1224-1225, 1998.
59. Lo YM, Lo ES, Watson N, Noakes L, Sargent IL, Thilaganathan B, Wainscoat JS. Two-way cell traffic between mother and fetus: Biologic and clinical implications. Blood 88:4390-4395, 1996.
60. Welsh K. Scleroderma: Chimerism, the blind man, and the scientist. Lancet 351:540-541, 1997.
61. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: A study of 53 long-term-surviving patients. Transplantation 46:238-240, 1988.
62. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: Comparison with Sjogren syndrome and scleroderma. Br J Haematol 66:45-47, 1987.
63. Aractingi S, Dausset J, Carosella ED. Chimerism in scleroderma. Lancet 351:1886, 1998.
64. Connolly MK, McCalmont TH. Fetal DNA and cells in women with systemic sclerosis. N Engl J Med 339:771-772, 1998.
65. Hsieh TT, Pao CC, Hor JJ, Kao SM. Presence of fetal cells in maternal circulation after delivery. Hum Genet 92:204-205, 1993.
66. Hamada H, Arinami T, Hamaguchi H, Kubo T. Fetal nucleated cells in maternal peripheral blood after delivery. Am J Obstet Gynecol 170:1188-1193, 1994.
67. Aractingi S, Berkane N, Bertheau P, Le Goué C, Dausset J, Uzan S, Carosella ED. Fetal DNA in skin of polymorphic eruptions of pregnancy. Lancet 352:1898-1901, 1998.